Rajiv Kumar, M.D.

Closed for Enrollment

• A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects with Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome Rochester, Minn.

  The purpose of this study is to assess the effectiveness and safety of KRN23 administered to adult patients with inoperable tumor-induced osteomalacia or epidermal nevus syndrome.

• Cancer-Associated Muscle Atrophy and Weakness: An Investigation of Etiology Rochester, Minn.

  This study is designed to gain a better understanding of the mechanisms leading to muscle wasting and metabolic abnormalities in skeletal muscle of cancer patients.

• Evaluate the Effect of 1,25-Dihydroxyvitamin D3 Treatment on Insulin Secretion and Muscle Strength in Pre-diabetic Persons (KUMAR2) Rochester, Minn.

  The purpose of this study is to assess the effects of 1,25(OH)2D3 on insulin secretion by the pancreas and glucose utilization by skeletal muscle, as well as to determine the effects of 1,25(OH)2D3 on muscle strength in pre-diabetic subjects.

• Fractures and Bone Disease in Living Kidney Donors Rochester, Minn.

  The purpose of this study is to to determine whether or not prior living kidney donors have an increased risk of bone fractures. The study will also determine bone structure and health in prior living donors as compared to matched controls.  

   

   

   

   

  We will determine if living kidney donors are at increased risk of bone disease and fractures following kidney donation. This information will be valuable in informing future kidney donors of the risks of donation and in devising treatments, such as administration of vitamin D analogs like calcitriol, to prevent such complications.

• Maintenance and examination of pancreatic cancer cell lines Rochester, Minn. We wish to examine pancreatic adenocarcinoma cell lines to determine what genes are being expressed in the cells that might cause muscle wasting in patients. We will also perform chemical analyses of plasma obtained from these patients to identify substances that might be causing muscle wasting. Finally, we will examine proteins that are secreted by such cells to identify mediator is of cachexia or muscle wasting.